News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
Porton commits to reduce absolute scope 1 and 2 GHG emissions 42% by 2030 from a 2023 base year. Porton also commits to reduce absolute scope 3 GHG emissions covering purchased goods and services, fuel and energy related activities, upstream transportation and distribution, waste generated in operations, and processing of sold products 25% within the same timeframe.
“The recent validation of Porton’s carbon reduction near term targets by the SBTi underscores our commitment to addressing the global challenge of climate change. We will collaborate closely with our partners across the industrial chain to integrate low-carbon principles into every stage of our operations, from R&D and production to supply chain management. We also call on industry peers to join us in adopting science-based targets and collectively advance efforts to combat global climate change.” said Oliver Ju, Chairman and CEO of Porton.
Porton is implementing initiatives across several areas such as R&D process innovation, renewable energy transition, and streamlining production processes. Through energy structure transformation, operational excellence, and sustained technological innovation, we hope to drive measurable progress toward our carbon reduction targets.
About the Science Based Targets initiative
The Science Based Targets initiative (SBTi) is a collaboration between CDP, the United Nations Global Compact(UNGC) , World Resources Institute (WRI) and the World Wide Fund for Nature (WWF).
The SBTi defines and promotes best practice in science-based target setting and independently assesses companies’ targets.
About Porton
Founded in 2005, Porton Pharma Solutions Ltd. is an internationally recognized pharmaceutical contract development and manufacturing organization (CDMO) in enabling our global clients to optimize drug development and manufacturing. We provide customer development and manufacturing services for Small Molecules, Tides, Biologics and Conjugates (ADCs, AOCs, PDCs, RDCs, etc.), and Advanced Therapy Medicinal Products from pre-clinical to commercialization stages.
Others
More
News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
News 2025-03-07
Porton Wins Outsourced Pharma 2025 CDMO Leadership Award
In March 2025, Porton Pharma Solutions Ltd. was honored with the "Global Small Molecule API Award" at the 14th Outsourced Pharma CDMO Leadership Awards, recognizing its exceptional end-to-end services across the global small molecule drug lifecycle. This award reaffirms Porton's outstanding performance in the CDMO sector for pharmaceutical R&D and manufacturing worldwide.
